Clinical trials: Excimer Light
Acne Vulgaris
Adjunctive 308-nm Excimer Light With Oral Azithromycin for Inflammatory Acne
This randomized, evaluator-blinded, split-face study evaluated whether adjunctive lesion-directed 308-nm excimer light improves inflammatory acne outcomes during oral azithromycin therapy.
- Trial name
- NCT07777952
- Testing
- 308-nm Excimer Light, Azithromycin
- Where
- Egypt
- Volunteers
- 32 people
- Sponsor
- Mahmoud Rageh
Adipose-derived Stem Cells, Excimer Light
Adipose-derived Stem Cells Combined With Excimer Light in the Treatment of Stable Vitiligo
This study aimed to assess the efficacy and safety of intradermal injection of adipose-derived stem cells, alone and combined with excimer light in treatment of stable vitiligo.
- Conditions
- Adipose-derived Stem Cells, Excimer Light, Stable Vitiligo
- Trial name
- NCT07690501
- Testing
- Adipose-derived Stem Cells Combined With Excimer Light
- Where
- Egypt
- Volunteers
- 15 people
- Sponsor
- Tanta University
Alopecia Areata
Excimer Light and Topical Steroid in Treatment of Alopecia Areata
Alopecia areata is a polygenic autoimmune disease causing hair loss, particularly during the anagen phase of hair growth This condition has a lifetime risk of about 2.1% of the world population and the cumulative incidence seems…
- Trial name
- NCT04793945
- Testing
- topical steroid and 308nm-Excimer light therapy
- Volunteers
- 30 people
- Sponsor
- Assiut University
Vitiligo, Excimer Laser
Effect Of Topical Prostaglandin F2α Analogs,Fractional CO2 Laser, Excimer Laser Or Their Combination In Treatment Of Vitiligo
Vitiligo is a chronic disease with an unpredictable clinical course, characterized by the appearance of white macules and patches on the skin and mucous membranes due to the disappearance of melanocytes in the affected area.
- Conditions
- Vitiligo, Excimer Laser, Fractional CO2 Laser
- Trial name
- NCT04577027
- Testing
- Topical travoprost 0.004% solution, Fractional CO2 laser, Excimer laser
- Volunteers
- 30 people
- Sponsor
- Assiut University
Vitiligo, Generalized
Catecholamines Level in Vitiligo Patients Before and After Excimer Light
Vitiligo is an acquired cutaneous disorder of pigmentation, with a 1-2% incidence worldwide, without predilection for sex or race.
- Trial name
- NCT04803461
- Testing
- serum and urinary catecholamines
- Volunteers
- 21 people
- Sponsor
- Assiut University
Vitiligo, Non-Segmental Vitiligo (NSV)
Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.
The goal of this clinical trial is to learn if topical application of crisaborole 2% ointment can treat stable patches of facial vitiligo in pediatrics and adult patients of both genders.
- Conditions
- Vitiligo, Non-Segmental Vitiligo (NSV), Stable Vitiligo
- Trial name
- NCT07904910
- Testing
- Crisaborole 2% topical ointment, tacrolimus 0.1%, Excimer Light therapy
- Where
- Egypt
- Volunteers
- 35 people
- Sponsor
- Cairo University
Vitiligo, Generalized
Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo
The study aims to evaluate the safety and efficacy of the combination of topical baricitinib and 308-nm monochromatic excimer light versus 308-nm monochromatic excimer light alone in treatment of non-segmental vitiligo.
- Trial name
- NCT05950542
- Testing
- Baricitinib
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University
Vitiligo - Macular Depigmentation
0.005% Latanoprost Gel for Nonsegmental Vitiligo
Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation.
- Trial name
- NCT07016113
- Testing
- 0.005% latanoprost gel, 0.1% mometasone furoate cream
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- Universitas Padjadjaran
Vitiligo, Nonsegmental Vitiligo
Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo
This randomized comparative study will evaluate the efficacy and safety of topical ruxolitinib 1.5% cream compared with topical tacrolimus 0.1% ointment, each combined with 308-nm excimer laser therapy, in patients aged 12 years…
- Trial name
- NCT07909668
- Testing
- Tacrolimus 0.1% ointment, Ruxolitinib 1.5% cream, 308-nm excimer laser
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Kafrelsheikh University